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Executive summary 
 
Cancer in young people is rare, but it is still a major health issue in Europe. Each year, more 
than 6,000 young people in Europe die of cancer. There are more than 300,000 European 
childhood cancer survivors (in 2020, they will be nearly half a million): two-thirds of them 
have some late side effects of treatment, that are severe and impact on the daily life of half 
of those affected.  
 
Within the European Network for Cancer research in Children and Adolescents (ENCCA), 
SIOPE and the European paediatric haematology-oncology community have established a 
long-term sustainable Strategic Plan to increase the cure rate and the quality of 
survivorship for children and young people with cancer over the next ten years. The 
ultimate goal is to increase the disease- and late-effect- free survival after 10 years from the 
diagnosis, and beyond. 
 
Seven medical and scientific objectives have been set up to achieve these goals:  
1. Innovative treatments: to introduce safe and effective innovative treatments (i.e. new 
drugs, new technologies) into standard care; 
2. Precision cancer medicine: to use improved risk classification as well as biological 
characteristics of both the tumour and patient (such as molecular and immunological 
factors) to help guide decisions on which therapies to use; 
3. Tumour biology: to increase knowledge of tumour biology and speed up translation from 
basic research to clinical care to benefit patients; 
4. Equal access: to bring about equal access across Europe to standard care (in both 
diagnosis and treatment), expertise and clinical research; 
5. TYA: to address the specific needs of teenagers and young adults (TYA), in cooperation 
with adult oncology; 
6. Quality of survivorship: to address the consequences of cancer treatment such as long-
term side effects, to better understand the genetic background/risk of an individual, and 
to improve quality of life of childhood cancer survivors; 
7. Causes of cancer: to understand the causes of paediatric cancers and to address 
prevention wherever possible. 
 
SIOPE will steer and coordinate the effective implementation of this Strategic Plan, 
together with the European Clinical Trial Groups (ECTGs) and the National Paediatric 
Haematology Oncology Societies (NAPHOS),  in close cooperation with the parents, patients, 
and survivors’ advocates from the European Regional Committee of Childhood Cancer 
International (CCI).  
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Cross-tumour platforms and projects will facilitate this implementation: a Clinical Trial 
Facilitating (CTF) platform to ease setting up of clinical trials within the new EU Clinical Trial 
Regulation, the PICORET (Population Improvement in Childhood cancer Outcomes through 
Research, Evaluation and Training) outcome research project to evaluate and monitor 
progress in childhood cancer survival and therapy effectiveness, the QUARTET (Quality and 
Excellence in Radiotherapy and Imaging for Children and Adolescents with Cancer across 
Europe in Clinical Trials) project for quality assurance in radiation therapy, the CDDF-SIOPE-
ITCC multi-stakeholder platform to improve oncology drug development for children and 
adolescents, and the ‘Ethics and Social Science and Humanities’ project to address the 
ethical aspects related to paediatric cancer. An efficient IT infrastructure to support e-Health 
and research will be developed, and a European Reference Network for paediatric patients 
with cancer will be created to facilitate cross-border healthcare and access to expertise. The 
‘Oncopolicy’ programme will ensure that the needs of young people are well taken into 
account into all EU policy initiatives in the field of health and research. Finally, the ‘Education 
and Training’ programme will ensure an adequate training to paediatric oncology health 
professionals. 
 
Partnerships will be strengthened with patients, parents and survivors’ advocates, adult 
oncologists as well as paediatric oncologists from other continents. ‘Intelligent and 
transparent’ public-private partnerships, recognizing the specificities of paediatric 
haematology-oncology, will be established with industry. The Strategic Plan’s projects and 
structures will be funded through European and national grants, as well as by charities and 
industry.  
 
In conclusion, as a result of several initiatives to involve all stakeholders and ensure that all 
their points of view would be taken into account in the document, this long-term sustainable 
Strategic Plan has achieved a broad consensus, and will serve as a ‘European Cancer Plan for 
Children and Adolescents’. 
 
 
Gilles Vassal, SIOPE President and ENCCA Activity Coordinator 
Ruth Ladenstein, ENCCA Coordinator 
Martin Schrappe, SIOPE President-Elect and ENCCA Activity Coordinator 
Kathy Pritchard-Jones, ENCCA Activity Coordinator 
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Cancer in young people in Europe 
 
Paediatric cancer is still a major public health issue, despite high survival rates compared 
to adult cancers 
 
 Each year there are 35,000 new cases of cancer in children and adolescents in Europe 
(15,000 in children below the age of 15 years and 20,000 in those aged 15-24). 
 1 out of 300 new-borns will develop cancer before turning 20. 
 80% are disease-free after 5 years from diagnosis, thanks to the currently available 
multidisciplinary treatments: 
o Today there are approximately 300,000 EU citizens surviving a childhood cancer. 
In 2020, they will be nearly half a million;  
o Two-thirds of survivors have late side effects of treatment, which are severe and 
impact on the daily life of half of those affected; 
o Beyond 5 years from diagnosis, disease-free survivors have a higher mortality 
rates than their non-affected peers. 
 6,000 young people die each year of cancer. 
 Despite improving survival rates, cancer is still the first cause of death by disease beyond 
one year of age in the EU. 
 Cancers in children differ from cancers in adults. The most frequent childhood cancers 
are leukaemias, tumours of the central nervous system (CNS), lymphomas and 
neuroblastomas. They occur from birth to adolescence, with 35% of the typical childhood 
cancers occurring before the age of five years. 
 Considering epidemiology and outcomes, there are three main groups of paediatric 
cancers: 
o Those with a good prognosis (with a higher than 85% chance of survival after five 
years) under current standard multidisciplinary treatments, using cytotoxic drugs 
in often an intensive mode (acute lymphoblastic leukaemia, lymphomas, 
retinoblastoma and renal tumours). Over the last five years, the survival rates 
have plateaued for patients suffering from these malignancies, while treatment 
intensity has been reduced for some patients in order to decrease the risk of 
long-term sequelae; 
o Those with a poor prognosis (~50% or less 5 year survival) such as acute myeloid 
leukaemia, several CNS tumours, neuroblastoma, bone and soft tissue sarcomas. 
Among these diseases, some have a very poor prognosis such as diffuse intrinsic 
pontine glioma, high-risk neuroblastoma and metastatic sarcomas; 
o The extremely rare tumours, for which there is a lack of information on their real 
incidence and survival. 
 CNS tumours (33%), leukaemias (29%) and neuroblastoma (8%) are responsible for 60% 
of cancer deaths amongst children aged 0 to 14 years.  
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Unequal access to standard care and research across Europe 
 
 Five-year survival is generally 10 to 20% lower in Eastern Europe, a disparity that 
becomes even larger for cancers which already have poor outcomes[2]. 
 There are already standards of care for paediatric oncology treatment centres [4], but 
these are not applied equally across Europe [5]. 
 Teenagers and Young Adults (TYA) aged 15 to 24 years have very specific needs which 
are not equally addressed across Europe and. there are still differences  in their 5 year 
survival when compared to younger children with the same malignancy. 
 
There has been little progress regarding difficult-to-treat diseases during the last five years 
 
 Progress has been made over the last 50 years by using intensive chemotherapy 
regimens (combined with surgery and/or radiotherapy in solid tumours). This includes 
improved outcomes in some cancers with poor prognosis such as high-risk 
neuroblastoma (40% survival with highly intensive chemotherapy regimens including 
immunotherapy) and acute myeloid leukaemia (60% survival with intensive 
chemotherapy and allogeneic hematopoietic stem cell transplantation). 
 Patient survival has plateaued over the last five years or more for difficult-to-treat 
diseases, which calls for innovative treatments with new mechanisms of action to control 
resilient and resistant diseases. 
Paediatric haematology-oncology in Europe 
 
Though the area of paediatric haematology-oncology is small, it is extremely complex and 
covers at least 60 different types of cancer in a population ranging from new-borns to 
teenagers, and even more when biological markers (“biomarkers”) are considered [6]. 
 
Strengths  
 
 Care and research are well integrated on a daily basis, and many high-level basic and 
translational research teams are dedicated to paediatric malignancies. 
 Approximately 350 European public specialised centres in paediatric university hospitals 
and comprehensive cancer centres take care of patients with a paediatric cancer, and 
private practice is extremely rare. 
 There is a strong awareness of the needs and challenges for childhood cancer survivors, 
with dedicated groups (e.g. PanCare, the Pan-European network for Care of survivors 
after childhood and adolescent cancer) encompassing both healthcare professionals and 
survivors.  
 Most clinical trials are run at the European level for each malignancy by well-organized 
European Clinical Trial Groups (ECTGs). 
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 Up to 90% of newly diagnosed patients are treated according to standard protocols or in 
prospective clinical trials. Up to 40% of patients are treated within therapeutic trials, 
both at diagnosis or at relapse, and clinical research is mainly led by academia, with 
industry-sponsored trials representing less than 5% of biomedical research. 
 The paediatric haematology-oncology community is accustomed to working together 
since more than 50 years, with a strong track record of publishing peer reviewed 
research. 
 
Weaknesses 
 
 There is a lack of sustained and sufficient funding, with high levels of competition for 
funding and need for prioritisation. 
 Healthcare professionals struggle to run investigator-driven clinical trials since the entry 
into force of the EU Clinical Trial Directive (2001/20/EC) in 2004. Although the new EU 
Clinical Trial Regulation (536/2014/EU) may facilitate academic research when it will be 
implemented (in 2016), however, it will not address all the existing challenges.  
 There is still poor access to new paediatric drugs in Europe, despite the EU Paediatric 
Medicine Regulation (1901/2006/EC and 1902/2006/EC) – which nevertheless changed 
the landscape of childhood cancer drug development in Europe. 
 There is insufficient integration between basic biology and clinical research, although 
there have been several successful EU projects (including KidsCancerKinome, EET-
pipeline, ChildHope) funded within the 5th and 6th Framework Programmes. 
 There are considerable disparities in Europe in the implementation of research (clinical, 
translational and basic) and in access to standard care, in particular for TYA. 
 Paediatric haematology-oncology is not recognised as a sub-specialty in most countries. 
 Parents, patients and survivors’ organizations lack tools and platforms to better join 
forces with all stakeholders. 
 A certain level of fragmentation of research remains, in spite of a long history of 
networking and major efforts to build together a common infrastructure. 
 Paediatric haematology-oncology has grown and achieved successes so far in relative 
isolation in comparison with the adult oncology community.  
 
Opportunities 
 
 The availability of high-throughput technologies that can quickly deal with large numbers 
of samples will allow new breakthroughs in understanding paediatric tumour biology . 
 The development of effective innovative therapies (such as targeted agents and 
immunotherapy) in adult cancers should be applicable to the treatment of paediatric 
tumours. 
 Paediatric haematology-oncology is now part of the EU agenda, as illustrated by ENCCA – 
a FP7 network of excellence structuring paediatric cancer research in Europe – and ExPO-
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r-Net, a DG SANTE project piloting the concept of European Reference Networks (ERN) 
within the scope of the EU Cross-Border Healthcare Directive (2011/24/EU). 
 There has been a strong commitment by the Members of the European Parliament to 
support the paediatric haematology-oncology agenda, for instance via their 
endorsement of the SIOPE-ENCCA-ICCCPO Manifesto for Paediatric Oncology.  
 Advocacy groups of parents, patients and survivors advocates are increasingly well 
organized in Europe (through Childhood Cancer International (CCI), formerly ICCCPO) and 
are strongly committed and equal partners in the European care and research agenda. 
 Charities in several countries are committed to support and finance research 
programmes on cancer in children and teenagers. 
 
Threats 
 
 There is a possibility that due to factors such as a high cure rates, decision-making 
leaders at the European and national levels might consider that paediatric cancer is not a 
priority, supposing that all efforts should be concentrated only on cancer prevention in 
adults and on transforming cancer into a controlled chronic disease in the ageing 
population. 
 The global economic crisis hindered the capacity of several EU Member States to 
improve their healthcare system to deliver standard treatments for young people with 
cancer. 
 There is limited access to some essential medicines, due to drug shortages and to the 
high price of new medicines. 
 Issues around the lack of collection of data in patients with diseases that have a good 
prognosis under standard treatment mean that the quality of care and, eventually, the 
probability of cure will be decreased. 
 Wide-ranging EU regulatory initiatives might negatively impact the implementation of 
the goals of the paediatric haematology-oncology community, for example the EU 
General Data Protection Regulation (2012/0011(COD)) under discussion at the time of 
publication could impact on research and trials. 
 
Overall goals and objectives 
 
The overall goals over the next 10 years 
 
 To increase the cure rate for young people who have a cancer with a poor prognosis. 
 To increase the quality of life for survivors of childhood cancer. 
 
The measure of success will be 10 years free of disease and late side effects. 
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The seven objectives (with equal importance and weight) 
 
1. Innovative treatments: to introduce safe and effective innovative treatments (i.e. new 
drugs, new technologies) into standard care. 
2. Precision cancer medicine: to use improved risk classification as well as biological 
characteristics of both the tumour and patient (such as molecular and immunological 
factors) to help guide decisions on which therapies to use. 
3. Tumour biology: to increase knowledge of tumour biology and speed up translation from 
basic research to clinical care to benefit patients. 
4. Equal access: to bring about equal access across Europe to standard care (in both 
diagnosis and treatment), expertise and clinical research. 
5. TYA: to address the specific needs of teenagers and young adults (TYA), in cooperation 
with adult oncology. 
6. Quality of survivorship: to address the consequences of cancer treatment such as long-
term side effects, to better understand the genetic background/risk of an individual, and 
to improve quality of life of childhood cancer survivors. 
7. Causes of cancer: to understand the causes of paediatric cancers and to address 
prevention wherever possible. 
 
Key success factors to achieve these objectives 
 
 Both at the European and national levels, there is a need for better integration, 
coordination and improved long-term sustainability of research. This is especially when 
EU funding is more fragmented. 
 Commitment from all funding bodies to fund projects and structures relevant to these 
objectives (including the European Commission, national funding bodies, charities, 
industry, and investors). 
 The profile of paediatric haematology-oncology in the European cancer agenda should 
be strengthened, and its visibility increased through a more efficient communication 
strategy. 
 A strong partnership with parents, patients and survivors, including better 
communication and dissemination of information. 
 Levels of collaboration with adult oncology should be improved. 
 Being part of the global paediatric oncology agenda and developing further 
collaborations with other continents. 
 Building intelligent and transparent partnerships with industry. 
 Effective and appropriate European regulations are vital and must be encouraged and 
engaged with. 
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Objective 1: Innovative treatments 
 
To introduce safe and effective innovative treatments (i.e. new drugs, new technologies) 
into standard care 
 
Innovative oncology drugs with new mechanisms of action (MOA) are already available for 
adult cancers, and can be more effective than traditional drugs in several refractory 
malignancies. The field of drug development is currently expanding beyond well-studied 
areas like signalling pathways, to target patient’s immune system, as well as their unique 
genetic profile and metabolism. Despite recent EU regulatory initiatives that changed the 
landscape of paediatric drug development in Europe for the better, access of children and 
adolescents with cancer to innovative therapies remains insufficient and slow [7]. 
 
Strategy 
 
 To develop and deliver a new drug development strategy – by disease and across 
diseases –based on the specific biology of patients’ tumour, taking into account 
existing therapeutic strategies implemented by the ECTGs.   
 To provide a guide for efficient and innovative public-private partnerships between 
academia and the pharmaceutical industry, within the frame of the EU Paediatric 
Medicine Regulation. 
 
Actions 
 
1. Across Europe, increase the access of patients to new and innovative therapies, 
including better referral of patients, and install a molecular and immunological 
tumour portrait  as a standard of care at the time of relapse as well as at diagnosis 
for patients with a high-risk and resistant diseases (link with objective 2). 
2. Improve the evaluation of adult cancer drugs for use in the paediatric population, 
establishing a clear drugs’ prioritisation and avoiding unjustified waivers (not 
allowing an adult drug to be translated to children). 
3. Identify targets in paediatric cancers and, thus, develop specific paediatric anti-
cancer drugs (link with objective 3). 
4. Develop innovative technologies such a high precision radiation therapy and 
interventional radiology. 
5. Develop innovative designs and methods for efficient studies, both in early phase and 
phase III clinical trials. 
6. Influence changes  in the relevant regulations. 
7. Develop international academic collaboration and efficient cooperation with main 
stakeholders (patients, survivors, parents, academia, charities, industry, regulators, 
EU decision- and policy-makers). 
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The European new drug development programme will be implemented by the European 
consortium for Innovative Therapies for Children with Cancer (ITCC), in collaboration with 
the disease-specific European Clinical Trials Groups (ECTGs). 
Brought about by ENCCA, the CDDF (Cancer Drug Development Forum)- SIOPE -ITCC  
paediatric oncology platform was created in 2013 with academia, industry, parents and 
regulators in order to make proposals for improving new oncology drugs development for 
children and adolescents [8]. 
 
Objective 2: Precision cancer medicine  
 
To use improved risk classification as well as biological characteristics of both the tumour 
and patient (such as molecular and immunological factors) to help guide decisions on which 
therapies to use 
 
Risk stratification is used in paediatric haematology-oncology to adapt the intensity of 
patients’ treatment to their own individual risk of failure. It is part of standard of care, is 
based on the extent of the disease and, increasingly, on tumour biology and response (e.g. in 
neuroblastoma and leukaemias) [9] [10] [11]. There has been recent progress in the 
classification of several paediatric malignancies (such as medulloblastoma, high grade 
glioma, ependymoma and rhabdomyosarcoma) based on specific aspects of their biology 
[12]. This will lead to new “biomarkers” that can be used in clinical practice to improve risk 
stratification and to better adapt existing and new treatments (objective 1) to each patient.  
 
Strategy 
 
 To analyse the specific biology (molecular profiling) of both the patient and tumour at 
the point of diagnosis and throughout treatment to improve risk stratification for 
adapted individual treatment by identifying: 
o Patients with a high probability of cure with standard treatment, who may be 
proposed new or reduced interventions to decrease the risk of late effects; 
o Patients with a poor prognosis tumour to whom innovative therapies should be 
proposed as early as possible, to increase their probability of cure. 
 
Actions 
 
1. Run prospective clinical trials with innovative design and methods to confirm the use 
of biomarkers and algorithms in risk stratification, treatment allocation and disease 
monitoring. 
2. Enhance the collaboration between specialists such as biostatisticians, clinicians and 
biologists. 
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3. Expand the availability and accessibility of biomarkers for clinical and research use by 
setting up a network of the necessary molecular laboratories. 
4. Develop research in functional imaging, set up a European imaging platform as well 
as a platform for quality control in radiation therapy. 
5. Improve data sharing, especially those that are linked, such as genomic and clinical 
data, and widen access of such information to researchers.  
6. Facilitate international academia-led clinical trials (via facilitated submission 
processes, shortening the time needed from conception to launch). 
7. Widen access to tumour samples and nucleic acids for researchers. 
 
This strategy will be implemented by the ECTGs developing research in each paediatric 
malignancy, and it will be facilitated by the cross-tumour European platforms and 
programmes set up within SIOPE. 
 
Objective 3: Tumour biology  
 
To increase knowledge of tumour biology and speed up translation from basic research to 
clinical care to benefit patients. 
 
Cancers in adults result from processes that have multiple steps, mainly following exposure 
to external carcinogens (tobacco, alcohol, UV, diet, etc.) and often progression over many 
years. In contrast, paediatric cancers develop early in life and over a much shorter time 
period, suggesting that fewer and stronger events are required for progression. They are 
rare, and most show fewer genetic defects and a lower genetic complexity as compared to 
adult cancers [13]. Major progress has been made in understanding paediatric tumour 
biology, leading to the discovery of unique cancer hallmarks that are also involved in cancer 
formation in adults, such as the RB1 gene in retinoblastoma and, more recently, Histones H3 
mutations in diffuse intrinsic pontine gliomas [12]. These advances have already resulted in 
new classification of several diseases. Additionally, the role of the immune system in 
controlling tumour growth is now well-established in many adult cancers, and the challenge 
is to translate this new findings into successful therapies.  
 
Strategy 
 
 To use modern and innovative technologies to further uncover the mechanisms of 
paediatric tumour development, progression and relapse. Also, to explore the genetic 
and cellular heterogeneity within the same tumour, the regulation of genes 
(epigenetics), and the role of the immune system, metabolism and the tumour’s own 
surroundings (micro-environment).  
 To accelerate the translation of results from research to clinical care and allow patients 
to benefit from new knowledge in a timely fashion. 
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Actions 
 
1. Strengthen international networks of basic research teams, grouping them by 
different cancer types, and improve access to new pharmaceutical compounds for 
preclinical research. 
2. Enhance interactions between bio-informaticians, system biologists and 
developmental biologists. 
3. Increase interactions between basic scientists and clinical researchers. 
4. Share the clinical-biological data generated by the introduction of technologies that 
analyse the biology of specific tumours (such as high-throughput sequencing and 
other tumour profiling technologies) between clinicians and researchers. 
5. Improve the access of researchers to relevant and high quality clinically annotated 
biological samples (including tumour samples, circulating cells, circulating DNA).  
6. Increase the involvement of patients and parents in the precision cancer medicine 
agenda. 
 
Within ENCCA, several networks of tumour researchers that connect basic and translational 
research teams with a common interest in each paediatric malignancy have been developed. 
 
Objective 4: Equal access  
 
To bring about equal access across Europe to standard care (in both diagnosis and 
treatment), expertise and clinical research 
 
Treating children with cancer is a complex matter, and needs the expertise of a highly 
specialised multidisciplinary team. Across Europe, there is a 10 to 20% difference in 5 year 
survival, between countries with population-based cancer registration – the differences may 
be much greater where no such outcome data currently exist. SIOPE led the preparation, 
definition and dissemination of the ‘European Standards of Care for Children with Cancer’, 
and a recent SIOPE survey within the European Partnership for Action Against Cancer 
(EPAAC) showed that there is a wide disparity in the implementation of these standards of 
care across different European countries [4]. 
 
Strategy 
 
 To ensure that all centres in Europe that treat children and TYA with cancer meet the 
European Standards of Care for Children with Cancer; 
 To develop pathways that, for complex treatments and rare diseases/situations, 
allow access to specialised expertise, specialised technologies (i.e. specialised 
 
 
Page13/43 
surgery, radiotherapy techniques, haematopoietic stem cell transplantation) or 
clinical research (i.e. early phase trials of new treatments). 
 
Actions 
 
1. Build a European Reference Network (ERN) in paediatric haematology-oncology 
within the EU Cross-Border Healthcare Directive (2011/24/EU): 
 Create tumour boards by disease – to be considered at three levels: institutional, 
national and European – in order to provide advice on the best appropriate 
treatment and care for individual patients; 
 Identify centres that are able to deliver standard care and treatments (specialist 
centres) as well as hubs of coordination, which will also deliver complex 
treatments and specialised technology; 
 Improve referral to specialist centres and hubs of coordination within EU member 
states and across borders; 
 Set up an efficient e-Health and IT platform. 
2. Warrant availability of essential medicines for all patients. 
3. Specifically address the needs of children and adolescents with extremely rare 
cancers (e.g. adult cancers such as thyroid cancer, breast cancer and melanoma – 
occurring extremely rarely in the paediatric population – and extremely rare specific 
paediatric malignancies such as pleuropulmonary blastoma, etc.). 
4. Ensure that paediatric cancer registries cover all European countries, in order to 
adequately monitor the effects of the present Strategic Plan, and ensure that each 
National Cancer Plan addresses the specific needs of children and adolescents with 
cancer. 
5. Significantly improve access to palliative care for young patients at the end of their 
lives. 
6. Provide high quality training for all health professionals across Europe, and make 
paediatric haematology-oncology a recognised sub-specialty. 
 
The ExPO-r-Net project, funded by DG SANTE, is currently piloting the concept of a European 
Reference Network (ERN) in paediatric haematology-oncology, which specifically addresses 
the topic of extremely rare cancers and long-term follow-up. 
 
Objective 5: Teenagers and Young Adults  
 
To address the specific needs of teenagers and young adults (TYA), in cooperation with adult 
oncology 
 
Although cancer in teenagers and young adults (TYA) is rare, it is a substantial cause of death 
in this population. Outcomes are often poorer than in younger patients with the same 
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cancer, and several contributory factors have been identified: the type of tumours, their 
biology and sensitivity to current therapies, as well as the low participation of TYA in clinical 
trials [14] [15]. TYA have specific and unmet needs, including complex psychological and 
social supportive care. Their position between adult and children’s services in healthcare 
systems does not allow for the best possible provision of care or dedicated research that 
could improve their quality of survival.  
 
Strategy 
 
 To develop a comprehensive multidisciplinary European programme, tackling all issues 
and specific needs of the TYA population. This will be a joint integrated programme 
between paediatric and adult oncology, in strong partnership with patients. 
 
Actions 
 
1. Create a European multidisciplinary network on TYA cancers that covers care and 
research and includes all health professionals and patients. 
2. At the national level, help the creation of TYA cancer services, which provide the 
required complex multidisciplinary care. 
3. Define a training programme for health professionals addressing the specific needs of 
TYA. 
4. Increase the portfolio of clinical trials for TYA, and increase their accessibility to all TYA 
patients. 
5. Monitor progress in TYA terms of survival, using the clinical epidemiology platform 
(defined later in this document). 
 
Within ENCCA a pilot project has been initiated in order to build the European Network for 
Teenagers and Young Adults Cancer [14].  
 
Objective 6: Quality of survivorship 
 
To address the consequences of cancer treatment such as long-term side effects, to better 
understand the genetic background/risk of an individual, and to improve quality of life of 
survivors of childhood cancer. 
 
With an 80% survival at five years, the number of childhood cancer survivors (currently 
estimated to be more than 300,000 in Europe) is likely to continue to increase, and 
improving their quality of life is a major goal. Two-thirds of survivors have late-occurring side 
effects due to their treatments, which are severe in half of them, and have a strong impact 
on their daily lives. It is anticipated that in 2030 there will be around 750,000 paediatric 
cancer survivors in Europe.  
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The PanCare network was created in 2008 to address this issue [16]. PanCare is a pan-
European multidisciplinary network of health professionals, survivors of paediatric cancer 
and their families, who collaborate to reduce the frequency, severity and impact of late 
treatment side effects, with the aim of ensuring that every survivor of childhood cancer 
receives the best possible long-term care. In addition, several survivors’ associations were 
created recently to empower survivors and to help them tackle the issues raised above. 
 
Strategy 
 
 To improve awareness of the needs of childhood cancer survivors, together with 
them, and facilitate research on it. 
 To empower survivors to take the responsibility for their own follow-up, ensuring 
that they are well-informed on what to be aware of, how and when to access care 
and follow-up, and who to turn to if and when they need to. 
 To encourage health organisations to address the issues of long-term follow-up and 
ease the transition to adult medicine. 
 To run prospective clinical research to reduce the likelihood of long-term side effects 
in patients who have a good prognosis malignancy. 
 
Actions 
 
1. Establish guidelines for follow-up that cover all possible late-occurring side effects of 
current treatments. 
2. Create and provide a ‘Survivorship Passport’ for each child and adolescent treated for 
cancer that will include: 
 History and summary of the patient’s disease as well as treatments received; 
 Relevant follow-up measures, including precautionary measures to improve their 
quality of life; 
 A database to store the patient’s clinical data and help monitoring and research. 
3. Set up a relevant model of care to allow for a smooth transition to adult medicine 
(such as ‘long-term follow-up clinics’). 
4. Increase research on late-occurring side effects (for example cardiac toxicity, 
secondary tumours and infertility) and on quality of survival, including societal and 
psychological aspects. 
5. Anticipate long-term toxicities of innovative therapies, such as targeted therapies, 
that will be introduced in standard treatments. 
 
Two ongoing FP7 European projects, PanCareSurFup and PanCareLIFE, carry out research on 
late-occurring side effects [17]. The pilot initiative of the ‘Survivorship Passport’ is being 
developed thanks to the support of ENCCA and PanCareSurFup, and the organisation of care 
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including a virtual late-effects advisory centre, will be also addressed within the ExPO-r-NET 
project. 
 
Objective 7:  Causes of cancer 
 
To understand the causes of paediatric cancers and to address prevention wherever possible 
 
“Why does my child have cancer?” is a crucial question for parents, which most of the time 
receives no answer. Relatively few causative factors have been identified so far for childhood 
cancers. It is estimated that 4-8% of paediatric cancers occur within a known genetic 
predisposition and more than 100 genetic syndromes with a risk of cancer in childhood are 
known. The proportion may increase as more and more rare cancer gene mutations are 
discovered through ongoing analyses in areas such as genomics. Some studies already 
suggest that up to one in four children and adolescents with a history of cancer may have a 
genetic predisposition condition [18]. The identification of the genetic basis of rare inherited 
cancers in children has revealed key pathways that are shared with sporadic tumours, even 
in adults. Sequencing of the whole genome will generate new information that can be used 
to improve care and to identify new genetic hallmarks of cancer, which can be turned into 
targets for new therapies. 
 
Strategy 
 
 To increase research focused on predisposition to childhood cancer and on the 
oncogenic drivers that increase the risk of childhood cancer by: 
 Using whole genome sequencing to further uncover genetic predisposition to 
paediatric cancers; 
 Carefully addressing the pragmatic and ethical issues of genetic testing and 
counselling, anticipating that DNA testing is becoming widely available; 
 Addressing questions on the environmental causes of paediatric cancer through 
scientifically-led and evidence-based studies. 
 
Actions 
 
1. Create a European consortium on genetic predisposition to childhood cancers in 
order to coordinate research and guide implementation of new knowledge in the 
clinical setting; 
2. Provide guidelines and train health professionals on how to identify patients with a 
possible genetic predisposition, and how to inform parents; 
3. Improve access to paediatric oncogeneticists and genetic testing in Europe; 
4. Develop new strategies for prevention and monitoring, including through early 
diagnosis and screening; 
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5. Run high-resolution studies through the SIOPE clinical epidemiology platform 
(defined later in this document), to determine the role of external risk factors. 
 
Coordination and implementation of the Plan 
 
SIOPE is the European Society of Paediatric Oncology and is dedicated to care, research and 
training in paediatric haematology-oncology as well as policy-making for decisions that 
impact on cancer (‘oncopolicy’). 
 
Its mission is to ensure the best possible care and outcome for all children and young people 
with cancer in Europe, by increasing the cure rate and the quality of cure of children with 
cancer. More specifically, SIOPE is in charge of: 
 To coordinate the implementation of the European Strategic Plan; 
 To steer the integration of research, care and education, and increase funding levels; 
 To ensure that the EU legislative framework facilitates the implementation of the 
Strategic Plan; 
 To strengthen partnerships with all stakeholders. 
 
SIOPE is the European branch of the International Society of Paediatric Oncology (SIOP) and 
a founding member of the European Cancer Organization (ECCO). 
 
Currently there are 18 European Clinical Trial Groups (ECTGs) developing clinical and 
translational research either by an individual disease type (15 groups) or across multiple 
diseases (4 groups), who define and run their own research strategy according to the SIOPE 
Strategic Plan. In Europe there are also 25 National Paediatric Haematology-Oncology 
Societies (NaPHOS). The Chairs of ECTGs and NaPHOS form the SIOPE Clinical Research 
Council (CRC, formerly ECRC).  
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Legend. 
Members of SIOPE (EU) 
Members of SIOPE (non-EU) 
 
 
Childhood cancer from a societal perspective 
 
From an international perspective, paediatric oncology research in Europe is in good 
standing. Between 2005 and 2014, there were 32,785 academic papers about paediatric 
oncology, representing 4.6% of all oncology papers and 7.1% of all paediatric papers. 22% of 
those articles came from Europe and 32% from the US[19].  
 
In 2008, funding for paediatric oncology research was estimated, using previously validated 
econometric analysis of research activity [20], to be 1,229 USD millions, with more than 50% 
from public funding, including international funding such as European framework funding 
and just under 20% from the pharmaceutical industry [21]. In 2013, this has been estimated 
to have dropped to 900 USD millions, a decline over 25% over five years. 
 
Research output is growing, particularly in clinical research, but availability of short-term 
funding is getting worse despite more European programmes. In addition, most of the public 
policy discourse has been focused on an ageing European society and the needs of children 
with cancer are not high on the political radar, despite the fact that cancer is the leading 
cause of death by disease in the young population. Globally, childhood cancer is being 
heavily marginalised. 
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The SIOPE objectives are: 
 To improve public, political and policy visibility of childhood cancer research; 
 To show the existing linkage between research activity and better outcomes for children 
with cancer in Europe; 
 To develop strategies in order to broaden research engagement; 
 To address both pan-European research funding and national funding streams, as well as 
funding from charities. 
 
 
 
Facilitating platforms and cross-tumour research projects 
 
Platform to facilitate the implementation of ECTGs research strategy: the Clinical Trial 
Facility (CTF) Platform 
 
This platform will help institutions to set up international clinical trials in the framework of 
the new EU Clinical Trials Regulation (536/2014/EU), and will allow researchers to share their 
experiences and solutions to issues related to the Regulation’s implementation. It will 
provide templates and advice for the hurdles faced (e.g. practicalities and contracts) when 
implementing non-commercial clinical trials across multiple countries and sites, including the 
specific issues arising when trials are run in partnership with the pharmaceutical industry. 
Within ENCCA, a consortium of five European academic institutions has been created to 
speed up the implementation of early phase investigator supported trials. 
 
Clinical epidemiology platform for outcome research – The PICORET project  
 
The Population Improvement in Childhood Cancer Outcomes through Research, Evaluation 
and Training project (PICORET) will address the needs of clinical epidemiology and outcome 
research in paediatric haematology-oncology. Several paediatric cancers have a high survival 
rate with treatments that have been established through prospective European randomised 
trials. Population-based cancer registries measure overall but not relapse-free survival, and 
so there isn’t sufficient information on the effectiveness of first line therapy at a population 
level.  
 
PICORET will monitor the survival of all children and adolescents with cancer in Europe and 
evaluate progress across Europe using information from registries and observational studies 
that use standard treatments. Such ‘non-interventional’ clinical studies can assess 
effectiveness of biomarkers, which can be used for prognosis, and allow analysis of 
traditionally hard-to-research areas, such as surgical and imaging techniques. Through 
building enhanced clinical registry capabilities, PICORET will prospectively collect detailed 
clinical and biological information that can be used for quality improvement of diagnostics 
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and treatment pathways for patients treated by a standard treatment  outside of clinical 
trials. PICORET will monitor the survival of all children and adolescents with cancer in 
Europe, and will evaluate and compare the quality and effectiveness of treatments. High 
resolution studies will be run.  
 
Initially, PICORET will focus on renal tumours, neuroblastoma and medulloblastoma as its 
first exemplars. It will develop standardised clinical guidelines as well as a standardisation 
and quality programme in standard care, with a special focus on infant dosing. Twinning 
between institutions in countries with higher and lower survival rates will be introduced. 
Data privacy will be carefully monitored, and the project’s impact will be assessed. 
Platform for quality assurance in radiotherapy – The QUARTET project 
 
Quality assurance and quality control are mandatory when patients receive radiation 
therapy. This is to make sure that each patient gets the best treatment in terms of 
maximising effectiveness and minimising long-term side effects. However, they are not 
systematically performed within clinical trials and various programmes are implemented 
only in a limited number of EU countries.  
 
The QUARTET project (‘QUAlity and excellence in RadioTherapy and imaging for children and 
adolescents with cancer across Europe in clinical Trials’) aims to build a radiation therapy 
quality assurance programme across all paediatric malignancies. It will be run in partnership 
with the European Organisation for Research on Treatment of Cancer (EORTC) and Aquilab 
for patients participating in clinical trials using radiation therapy and run by ECTGs. 
Eventually, the platform will expand its activity to patients treated outside of clinical trials. 
 
Multi-stakeholder platform for new paediatric oncology drug development – The CDDF-
SIOPE-ITCC platform 
 
This multi-stakeholder platform was created in December 2013 by Cancer Drug 
Development Forum (CDDF)-SIOPE-ITCC as a deliverable of the ENCCA project – to improve 
oncology drug development for children and adolescents [8].  
 
Academia, parents and survivors, industry and regulators are equally represented and work 
together on the following objectives: 
 To set up drug prioritisation and enable drug development, based on the mechanism 
of action of the drug as well as biological factors; 
 To propose changes in the EU Paediatric Medicine Regulation to better address the 
needs of those with life threatening diseases; 
 To propose new incentives for the development of specific paediatric drugs and 
repurposing of existing drugs; 
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 To implement long-term follow up measures for new oncology drugs for children and 
adolescents. 
 
Ethics, Social Sciences and Humanities programme 
 
This is a natural development of the ethics programme set-up within ENCCA to maintain and 
improve the level of expertise on ethics in the field of paediatric cancer care and research. It 
is based on two priorities, namely to reflect the multidisciplinary nature of social sciences 
and humanities where suitable to paediatric oncology, and to facilitate access to appropriate 
expert views from professionals and from patients’ representatives on ethical issues.  
 
Following these priorities, “ethics” is meant as a multidisciplinary approach to the non-
technical issues related to the care, protection, and self-realisation o of paediatric oncology-
haematology patients (or former patients). It is proposed to develop a non-prescriptive, 
participatory and outcomes-oriented approach to these issues, harnessing the relevant 
knowledge and expertise in the Social Sciences and Humanities (SSH) field.  
 
Four main topics will be addressed by this programme: i) return of research results, ii) 
personal data in care and research environments, iii) access to medical innovation, iv) care 
and healthcare pathways. The programme will be performed through objective assessment 
of the non-technical issues related to the care and quality of survival of children and 
adolescents with cancer, as well as through community-based participatory research actions 
within the paediatric oncology community. 
 
In accordance with the successful implementation within ENCCA, the programme will be 
steered and run by a permanent contact point along with ad-hoc academic collaborations. A 
steering Legal and Ethical Advisory Board will peer-review the projects and the results. The 
following tools will be set up: i) a thematic database of ethics expertise in Europe, identifying 
expert individuals and centres in Western and Eastern European Universities, ii) a database 
of local initiatives for bedside and benchside ethics, accessible to professionals and patients, 
iii) an initiative to establish multi-centre collaborations on non-technical interventions 
(fostering experience-sharing and multicentre evaluation). All this is expected to generate 
sustained community dialogue, concerted evidence generation as well as transverse 
capacity-building on non-technical domains, first of all on ethical issues.  
 
The SIOPE portal 
 
The portal set-up within the ENCCA project will be transferred to SIOPE after the end of the 
ENCCA project (December 2015). This online ‘one-stop-shop’ portal will support 
communication and interaction between everyone involved in implementing the strategic 
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research agenda. It will serve as a resource for documentation and as a platform for 
information exchange. 
 
Each patient will have a unique ID (EUPID) so that their data can be anonymised and shared 
between different databases. A pilot project for an integrated IT structure will allow 
information to be linked between sources (such as registries, clinical trial databases, hospital 
electronic health records) and users (such as researchers and analysts) is being developed by 
the IT providers of ENCCA. 
 
Within ENCCA, a consultation IT platform has been developed for patients with 
haepatoblastoma (a very rare disease) by SIOPEL along with CINECA. This platform (including 
pathology slides and images) facilitates access to expert advice for diagnosis and treatment, 
including indications of liver transplant. This IT tool is further developed within the ExPO-r-
Net project for retinoblastoma and extremely rare paediatric tumours, and will eventually be 
adapted for other diseases within the Paediatric Oncology Europe Reference Network. In 
addition, an IT platform for virtual tumour boards will be developed. 
 
Based on these experiences and following those pilot projects, SIOPE and ECTGs will define 
how to structure the best IT environment that will allow the implementation of the Strategic 
Plan. 
 
Network of biobanks 
 
Samples from patients and tumours, which are labelled with additional clinical information, 
are vital for the success of the SIOPE Strategic Plan. The aim of SIOPE is therefore to support 
a network of biobanks that can share data electronically, in keeping with EU data protection 
laws. The difficulty of the task is not underestimated .  
 
A vital step in the development of such a network within SIOPE is the introduction of a 
unique patient identifier (the above mentioned EUPID) for every paediatric cancer patient 
treated in Europe, as well as the development of standardised patient consent forms. These 
must be in line with national data protection laws in European countries, and allow for new 
developments in molecular analysis of tumour samples (particularly next-generation 
sequencing),  as well as the wishes of patients and parents and other ethical considerations.  
 
In addition to this, ENCCA guidelines are currently being finalised on the standards for 
tumour and other patient samples (e.g. blood and plasma) as well as related materials like 
DNA and RNA, and on the process of access and use. 
 
Cross-tumour programmes 
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Oncopolicy programme 
 
Several regulatory initiatives are of direct concern to paediatric haematology-oncology and 
the implementation of the SIOPE Strategic Plan. SIOPE has developed expertise and skills to 
monitor and influence the development of relevant European cancer health and research 
policy themes, and to ensure that the needs of the paediatric haematology-oncology 
community are taken into account when regulations are drafted or revised:  
 
 Each National Cancer Plan should address the needs of children and adolescents with 
cancer, according to the European Cancer Plan. 
 The Cross Border Healthcare Directive (2011/24/EU) was established in 2010. This is the 
framework for the development of the future paediatric oncology European Reference 
Network (via the ExPO-r-Net project). 
 The Clinical Trials Regulation (536/2014/EU) is expected to enter into force in 2016 and 
to facilitate academic trials, and SIOPE will help European institutions and ECTGs to 
implement their trials within the new Regulation (through the CTF platform, see above) 
and ensure that experiences, issues and hurdles encountered in paediatric haematology-
oncology are fed back to the relevant bodies. 
 The Data Protection Regulation (2012/0011(COD)) is under discussion at the time of the 
publication. In its current form, it would be detrimental to outcome research in 
paediatric oncology – a major objective of the SIOPE Strategic Plan – as well as to the 
interdisciplinary research collaborations involving different institutions, in order to 
ensure the best quality of care to the patient. SIOPE is joining oncology stakeholders to 
ensure that the needs of academic research and epidemiology are taken into account.  
 The Paediatric Medicine Regulation (1901/2006/EC and 1902/2006/EC) entered into 
force in 2007. The European paediatric oncology community is engaged in pushing for 
immediate changes to its implementation, in order to better address the unmet needs of 
children and adolescents with cancer. Because cooperation between all stakeholders 
(patients, survivors, parents, academia, industry, regulators) is crucial, the CDDF-SIOPE-
ITCC multi-stakeholder paediatric platform (see above) was created to propose the 
immediate changes and to prepare for the revision of the Regulation, which could occur 
in 2017. 
 In the 2015 Health programme, the European Commission called for a Joint Action on 
Rare Cancers that will be implemented jointly with EU Member States. This will provide 
the framework for the implementation of part of the SIOPE Strategic Plan and for 
cooperation with adult oncology in the field of rare cancers. 
 
In 2014, SIOPE effectively obtained the commitment of EU institutions and civil society 
representatives to support young people with cancer, through their endorsement of the 
SIOPE-ENCCA-ICCCPO Manifesto for Paediatric Oncology. This document was signed by 20 
members of the European Parliament, setting up objectives to advance childhood cancer 
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research, treatment and care. After the European elections, this document became an even 
stronger advocacy document for SIOPE on the long-term. 
 
Additionally SIOPE and the European paediatric haematology-oncology community will 
contribute to the development of oncopolicy in Europe in the fields of multidisciplinary care, 
access to innovation and development of e-Health. SIOPE will join efforts with the European 
CanCer Organisation (ECCO) along with European Society for Medical Oncology (ESMO) and 
other European societies. 
 
Training and education programme 
 
The aim of this programme is to encourage high quality clinical and basic research as well as 
the delivery of high quality care in paediatric oncology throughout Europe. This is a remit of 
SIOPE and focuses on the organisation of educational courses and on the revision of the 
training syllabus in paediatric oncology. 
 
SIOPE is involved in several training courses to develop the knowledge of health 
professionals on new and state-of-the-art therapies and allow them to gain more practical 
skills in the treatment of paediatric malignancies: 
 The SIOPE-ESO Masterclass in paediatric oncology: practice-oriented training with 
a focus on the application of the most recent research findings to clinical practice; 
 The ECCO-AACR-ASCO workshop on “Methods in clinical cancer research” in 
Flims, Switzerland: introduction of junior clinical oncologists to the principles of 
good and innovative clinical trial design and methods; 
 The SIOPE-ENCCA-ENTYAC European Course on the treatment of teenagers and 
young adults with cancer (TYA),centred around multiple disciplines; 
 The joint SIOPE-ESMO training programme on TYA. 
 
As part of the work of the European Academy of Paediatrics, SIOPE revised its previous 
syllabus with the aim of having a comprehensive document for the whole of the EU that 
details the requirements expected from a trainee in paediatric haematology-oncology. The 
new version of the syllabus proposes a programme containing core knowledge and practical 
aspects related to approaches for diagnosis and treatment that are essential for all trainees 
in paediatric haematology-oncology (available on the SIOPE website: www.siope.eu).  
 
Communication 
 
The SIOPE Strategic Plan relies on timely, relevant and tailored communication to target 
stakeholders Based on its expertise of information-sharing with members and leading EU 
projects’ dissemination, SIOPE has set up a communication strategy, encompassing the pan-
European haematology-oncology community, decision-makers and the general public.  
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The communication objectives are:  
1. Uniting the community: further increasing the profile of SIOPE as the main reference 
point for paediatric haematology-oncology in Europe, to stimulate cross-border 
exchange of best practices, to strengthen existing collaborations and to develop new 
ones; 
2. Raising awareness: by fostering the well-informed involvement and commitment of 
target stakeholders and by raising awareness of paediatric cancers across Europe in 
partnership with parents and survivors. 
3. Generating action: translating the needs of the Strategic Plan as well as the SIOPE 
position and requests into legislative, funding, advocacy, partnership-building and 
further communication initiatives. 
 
Partnerships 
 
Partnership with patients, survivors and parents 
 
Building a partnership with patients, survivors, and parents’ organisations is essential to 
achieve the goals of SIOPE in terms of research, equal access to standard care and expertise, 
advocacy when new policies are developed and strategic decisions made at the national and 
European levels. 
 
CCI is a worldwide childhood cancer organisation that represents families of children with 
cancer and childhood cancer survivor groups. SIOPE has been working with the CCI Europe 
Regional Committee for several years, including partnerships in several European projects 
and initiatives. 
 
In 2011 the PPAC within ENCCA was created with CCI Europe Region Committee members, 
and consists of representatives from different national parents and survivors organisations. 
Since then, they have been building networks between parent and survivor groups and 
organisations, disseminating health policy-related issues within Europe and improving the 
training of representatives of patients survivors and parents in clinical research to make 
them powerful advocates and partners in this field. ENCCA, SIOPE and PPAC also worked 
together in joint research and dissemination activities, as well as the development of a long-
term sustainable strategy for paediatric oncology in Europe, the SIOPE Strategic Plan and the 
seven medical and scientific objectives. 
 
SIOPE and the CCI Europe Regional Committee entered into a co-operative relationship in 
order to implement the European long-term Strategic Plan and to raise awareness on cancer 
in children and adolescents. They signed a Memorandum of Understanding that sets out the 
specific areas of cooperation along with the principles by which both parties will run the 
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partnership. The four areas are: i) ethics and social sciences and humanities, ii) access to 
standard of care and expertise, iii) improvements to the regulatory and political environment 
at the pan-European and national level, iv) research and development. 
 
Partnership with adult oncology 
 
During the last 50 years, paediatric oncology has developed in relative isolation. Improving 
the cooperation of all paediatric haematologists and oncologists was the crucial objective so 
that an effective European clinical research programme could be set up and address the very 
specific needs of children with cancers without reference to adult cancer services. 
 
It is now recognised that adult and paediatric oncology have a lot to share and learn from 
each other, and that collaboration is beneficial in order to address common goals and 
challenges: 
 Care and research for rare cancers, in terms of innovative methodology to 
evaluate new treatments and in terms of health care organisation models to 
provide access to expertise for patients suffering from rare and extremely rare 
cancers; 
 Care and research for TYA (see above); 
 Access to essential medicines, since most anti-cancer drugs are used to treat both 
adult and paediatric cancers, even though there are differences in the tumours; 
 European initiatives on care and research oncopolicies. 
 
SIOPE and ESMO (the European Society of Medical Oncology) have decided to develop a 
joint initiative to address those topics, and established a Memorandum of Understanding to 
help this collaboration. 
 
 
Partnership with paediatric haematology-oncology in other continents 
 
SIOPE is part of the global paediatric oncology agenda run by the International Society of 
Paediatric Oncology (SIOP). Several European-centred study groups have an international 
scope, and bring together global investigators to participate in a common clinical trials 
portfolio.  
 
The IBFM-study group is international, and patients from countries outside Europe 
participate to its leukaemia trials and translational research projects.  
 
More than a hundred institutions from Europe, Asia, Central and South America, Australia 
and New Zealand collaborate in SIOPEL, the SIOPE-liver study group. Early drug trial groups 
such as ITCC in Europe, the Pediatric Oncology Experimental Therapeutics Investigator’s 
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Consortium (POETIC) and Therapeutic Advances in Childhood Leukemia and Lymphoma 
(TACL) in North America, the Canadian C17 network, the Australia Children’s Cancer Trials 
group and the Children Oncology Group (COG) phase I consortium are working together to 
speed up the development of new anticancer agents. 
  
SIOPEN has built with COG and neuroblastoma groups from Japan, China and Australia a 
large clinical and biological database of more than 9,000 neuroblastoma patients in order to 
define and validate new staging system and new biological prognostic biomarkers through 
the International Neuroblastoma Research Group [9] [22]. Groups such as the SIOP-Renal 
Tumours Study Group support clinical trials groups in other continents that run studies using 
the same standard treatment backbones, adapted to local circumstances. 
 
The COG and the European Inter-group for Childhood non Hodgkin lymphoma (EICNHL) are 
currently running a randomised phase III clinical trial to evaluate the addition of rituximab, 
an anti CD20 monoclonal antibody, on standard intensive chemotherapy treatment in high-
risk Burkitt’s lymphoma. 
 
The European and American Osteosarcoma Study Group (EURAMOS) has successfully 
completed a large phase III study with partners, which included the COG, the European 
Osteosarcoma Intergroup, the Cooperative Osteosarcoma Study Group, and the 
Scandinavian Sarcoma Group. The EURAMOS Strategy Group, made up of these four multi-
national groups, as well as the relevant Australasian, French, Italian, Japanese, and Spanish 
osteosarcoma groups, is exploring options for collaboration on an even larger platform. 
 
In the next 10 years, international cooperation will be reinforced to evaluate innovative 
targeted drugs within extremely small and rare groups (defined by biomarkers), such as 
children with B-RAF mutated malignancies. Even in less rare clinical situations, international 
randomised clinical trials will be considered more regularly to speed up evaluation of 
innovative therapies. 
 
Partnership with industry 
 
For the last 50 years, progress has been made in curing paediatric cancers by running 
academic trials using anti-cancer drugs that are available in hospital pharmacy departments. 
Pharmaceutical companies have not developed their anti-cancer agents in the paediatric 
population, and nearly half of drugs used daily to cure cancer in children and adolescents do 
not have the regulatory official authorisation, stated in the ‘Summary of Product 
Characteristics’. 
 
In Europe this situation has significantly changed over the last five years because regulatory 
initiatives, first in the U.S. and then in Europe, obliged pharmaceutical companies to test 
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their drugs in the paediatric population when relevant. There was indeed an urgent need to 
access new drugs developed by pharmaceutical companies as early as possible during their 
development in adults, and to avoid families moving to the US to get access to innovative 
therapies in development. 
 
Thanks to the EU Paediatric Medicine Regulation, pharmaceutical companies and academia 
have started to work together, to evaluate oncology drugs within paediatric investigation 
plans. This is a learning curve for everyone since pharmaceutical companies are not 
accustomed to working with paediatric oncologists and vice versa. 
 
The goal is to develop ‘intelligent and transparent’ partnerships that recognise the 
specificities of paediatric haematology-oncology, i.e. a well-structured arena for clinical 
research, dealing with rare and complex situations, while the paediatric development of 
oncology drugs is, by definition, a pre-competitive research activity for pharmaceutical 
companies and competition to access rare patients makes no sense. 
 
A new model of cooperation between pharmaceutical companies, academia and public-
private partnership needs to be developed in order to adequately address the needs of 
children and adolescents with cancer and regulatory requirements. This is being addressed 
in the CDDF-SIOPE-ITCC paediatric oncology platform. In addition, a strategy will be 
implemented to encourage investment and partnership with small pharmaceutical 
companies to develop drugs against specific paediatric targets. 
 
Partnership with charities 
 
In several EU Member States, charities are extremely efficient at fundraising to support 
research and care for children and adolescents with cancer. These efforts are developed at 
the national level and can be fragmented, with significant differences between countries. 
 
Most research programmes are run at the European level, and there is a need to figure out 
how charities from different countries can be more efficient at jointly funding large and 
ambitious European programmes. 
 
SIOPE will propose to charities to fund and co-fund European projects and programmes. By 
defining, implementing and coordinating a long term sustainable Strategic Plan, SIOPE and 
the European paediatric haematology-oncology are willing to provide a transparent and 
clear visibility to the projects that will be run within a well-defined and integrated 
framework.  
 
Funding strategy 
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By definition, funding of the now established European strategy in paediatric haematology-
oncology will come necessarily from several sources: the European Commission, national 
funding bodies, charities and foundations, industry as well as  anyone willing to invest in 
paediatric oncology research and development. 
 
European funding is available for research projects through Horizon 2020 calls.  Projects in 
paediatric haematology oncology will be submitted to relevant European calls by SIOPE, 
groups and institutions as part of the implementation of the SIOPE Strategic Plan and 
referred as such in their application.   
 
The critical hurdle encountered in paediatric haematology-oncology, as well as in other 
research areas, is the lack of funding for structures that are needed to run a coordinated and 
integrated research agenda. To this extent, in 2011 the European Commission provided 
€12m to structure oncology research into children and adolescents. One of the best 
examples of the goals achieved is the long-term sustainable Strategic Plan described in this 
document. ENCCA illustrates how funding for a permanent structure is essential to achieve 
progress and deliver success. 
 
ENCCA will finish on December 2015 and the decision was taken that SIOPE will run the on-
going agenda. The key question is how to fund the projects, the programmes and the 
structures that are needed to implement the long-term sustainable strategy. 
 
At the end of the SIOPE-ENCCA event, which shared the European Strategic Plan with all 
stakeholders in Brussels in September 2014, the participants proposed to develop a 
European Cancer Plan for Children and Adolescents. This plan would show the commitment 
of the EU and its Member States to address childhood and adolescent cancers as a priority 
and a strategic objective for the European Union. Specific European initiatives would be set 
up to join efforts from the EU and its Member States for funding. In addition, it would allow 
other co-funding bodies to contribute to a pan-European initiative. 
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List of acronyms/glossary 
 
 Biobank:  A type of biorepository that stores biological samples (usually human) 
for use  
in research 
 Biomarker:   Generally refers to a measurable indicator of some biological 
state or  
condition 
 CCI:   Childhood Cancer International 
 CDDF:   Cancer Drug Development Forum 
 CNS:   Central Nervous System 
 COG:   Children Oncology Group 
 CRC/ECRC:   European Clinical Research Council for paediatric and 
adolescent  
oncology 
 CTF:   Clinical Trial Facilitating platform 
 DG SANTE:   Directorate General for Health and Food Safety, European  
Commission 
 EAC: (ENCCA)  Ethics Advisory Committee  
 ECCO:   European CanCer Organisation 
 ECTGs:   European Clinical Trial group(s) in paediatric oncology 
 EICNHL:    European Inter-group Cooperation on Childhood and Adolescent Non  
Hodgkin Lymphoma 
 ENCCA:   European Network for Cancer research in Children and Adolescents 
 EORTC:  European Organisation for Research and Treatment of Cancer 
 EPAAC:   European Partnership for Action Against Cancer 
 ERN:   European Reference Network(s) 
 ESMO:   European Society for Medical Oncology  
 EU:   European Union 
 EURAMOS:   European and American Osteosarcoma Study Group 
 FP5, FP6, FP7:  EU 5th/ 6th/ 7th Framework Programmes for research and innovation 
 Horizon 2020:  EU Programme for research and innovation (2014-2020) 
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 I-BFM:   International BFM Study Group 
 ITCC:   Innovative Therapies for Children with Cancer 
 LTS:   (ENCCA) Long-Term Sustainability (working group) 
 MAC:   Members of the Parliament (MEPs) Against Cancer group 
 MOA:   Mechanism(s) Of Action 
 NaPHOS:   National Paediatric Haematology-Oncology Society-ies 
 PanCare:   Pan-European network for Care of survivors after childhood and  
adolescent cancer 
 PanCareSurFup:  PanCare childhood and adolescent cancer SURvivor care and Follow- 
UP studies 
 PICORET:   Population Improvement in Childhood cancer Outcomes through  
Research, Evaluation and Training 
 PIP:   Paediatric Investigation Plan(s) 
 POETIC:   Pediatric Oncology Experimental Therapeutics Investigators'  
Consortium 
 PPAC:   (ENCCA) Parent and Patient Advocacy Committee  
 QUARTET:  QUAlity and excellence in RadioTherapy and imaging for children and  
adolescents with cancer across Europe in clinical Trials 
 SAB:   (ENCCA) Scientific Advisory Board 
 SIOPE:   SIOP Europe, the European Society for Paediatric Oncology 
 SIOPEL:   SIOPE-Epithelial Liver Tumour Study Group 
 SIOPEN:   SIOP Europe Neuroblastoma Group 
 SSH:   Social Sciences and Humanities project 
 TACL:  Therapeutic Advances in Childhood Leukemia and Lymphoma 
 TYA:   Teenagers and Young Adults 
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Quotes from stakeholders 
 
 “Researchers are an essential driving force in making successful cure for childhood 
cancer possible.” (Hermann van Rompuy, former President of the EU Council, Belgium) 
 “Children are desperate to enrol in new clinical trials, that in some cases can be the only 
hope for survival.” (Glenis WiIlmott, Member of the European Parliament, UK) 
 “Children and adolescents with cancer need to be treated within clinical trials and 
benefit from all the facilities required by standard of care.” (Marianne Naafs-Wilstra, 
parent advocate, VOKK, The Netherlands) 
 “All national cancer plans should have provisions for children and adolescents.” 
(Participants at the SIOPE-ENCCA Conference, 18-19 September 2014) 
 “The EU Data Protection Regulation is a debatable piece of legislation which could 
threaten childhood cancer clinical research” (Nikolaus Forgó, Institute for Legal 
Informatics, DE) 
 “The needs of children with cancer have not been high on the political radar” (Richard 
Sullivan, UK) 
 “Survivors of childhood cancer want a normal life.” (Sabine Karner, PPAC/CCI/PanCare, 
Austria) 
 “All European children and young people with cancer should have access to standards of 
care, expertise and clinical research.” (Participants at the SIOPE-ENCCA Conference, 18-
19 September 2014) 
 “Childhood cancer survivors in Europe should have access to adequate follow-up.” 
(PanCare partners: Sabine Karner, Austria; Lars Hjorth, Sweden; Riccardo Haupt, Italy) 
 “Europe should have a European Paediatric Cancer Plan addressing both care and 
research.” (Participants at the SIOPE-ENCCA Conference, 18-19 September 2014) 
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Figure legends 
 
 
Figure 1: Proportions of the 12 main tumour groups in children and adolescents in Europe  [1] 
 
 
 
Figure 2: 5 year age-standardized survival from childhood cancers diagnosed in Europe between 2005 and 2007. Survival 
for retinoblastoma is calculated for 0-4 years only, and survival for osteosarcoma is calculated for 10-14 years only. 
Figures were region weighted and those for all cancers together and CNS cancers were adjusted by case-mix [2] 
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Figure 3: Cause of death by different cancer (Courtesy of Eva Steliarova-Foucher). 
Percentage of all cancer deaths in children (age 0-14) in all 50 areas covered by population-
based cancer registries contributing data for years 2000-2007 to the European Cancer 
Observatory (N=6256) [3]. Causes of deaths are classified according to the ICD-10 (WHO, 
1992) 
  
 
 
Page38/43 
 
 
Figure 4: 5-year survival for acute lymphoid leukaemia diagnosed in 2000-2007 in 
European children by country Includes data for 15 860 cases. Data adjusted by age, sex, 
and period of diagnosis. *Country-weighted. [2] 
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Figure 5: Pie chart of national contributions to paediatric oncology research, 
2005-14; fractional counts.  European countries coloured blue with shading; 
North American countries red with shading; Asian countries yellow with 
shading. Credit: Institute of Cancer Policy, London, UK 
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The European Clinical Trial Groups 
By disease: 
Tumour Name Group Name Website 
Brain Tumour SIOPE Brain Tumour Group www.siope.eu/european-
research-and-
standards/european-
clinical-research-
council/ecrc/siope-brain-
tumour-group  
Ewing Tumour EURO- E.W.I.N.G. www.euroewing.eu/clinical
-trials/ee2012-trial 
Germ Cell Tumours Germ Cell Tumours  
Hodgkin ’s Lymphoma  EHL – European Hodgkins 
Consortium, EuroNet-PHL 
www.kinderkrebsinfo.de/in
dex_eng.html   
Langerhans Cell 
Histiocytosis 
Histiocyte Society www.histiocytesociety.org  
Leukemias and 
Lymphomas  
I-BFM – The International BFM 
Study Group 
www.bfm-international.org  
Liver Tumours  SIOPEL – SIOPE-Epithelial Liver 
Tumour Study Group 
www.siopel.org  
Myelodysplasia EWOG-MDS ewog-mds.de  
Neuroblastoma SIOPEN – SIOP Europe 
Neuroblastoma Group 
www.siopen.org  
Non-Hodgkin Lymphoma EICNHL – European Inter-group 
Cooperation on Childhood and 
Adolescent Non Hodgkin  
 
Osteosarcoma EURAMOS – European and 
American Osteosarcoma Study 
Group 
www.euramos.org  
Renal Tumours SIOP-RTSG – SIOP Renal Tumours 
Study Group  
www.siop-rtsg.eu  
Retinoblastoma EURbSG – European 
RetinoBlastoma Group 
 
Soft Tissue Sarcoma CWS – Cooperative 
Weichteilsarkom Studiengruppe or 
Cooperative soft Tissue Sarcoma 
StudyGroup  
 
Soft Tissue Sarcoma EpSSG – European Paediatric Soft 
Tissue Sarcoma Study Group 
www.epssgassociation.it  
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Across diseases:  
 
Tumour Name Group Name Website 
New Anticancer Agents ITCC – Innovative Therapies for 
Children with Cancer 
www.itcc-consortium.org  
Stem Cell 
Transplantation 
EBMT – European Group for Bone 
Marrow and Stem Cell 
Transplantation Paediatric Working 
Party 
www.ebmt.org  
Survivorship and Late 
Effects 
PanCare – Pan-European Network 
of for Care of Survivors after 
Childhood and Adolescent Cancer 
www.pancare.eu/en  
Very Rare Paediatric 
Tumours 
EXPeRT – European Cooperative 
Study Group on Paediatric Rare 
Tumours) 
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The National Paediatric Haematology-Oncology Societies (NaPHOS) 
 
Country NaPHOS/Group Website 
Austria AGPHO (Austrian Group for 
Paediatric Haemato-Oncology)  
www.docs4you.at  
Belgium BSPHO (Belgian Society of 
Paediatric Haematology 
Oncology) 
www.bspho.be 
Bulgaria Bulgarian Society of Paediatric 
Oncology 
 
Croatia Croatian National Group  
Czech Republic CPH (Czech Working Group for 
Paediatric Oncology) 
 
France SFCE (Société Française de lutte 
contre les Cancers et leucémies 
de l’Enfant et l’adolescent) 
sfce.sfpediatrie.com  
Germany GPOH (Gesellschaft für 
Pädiatrische Onkologie und 
Hämatologie) 
www.kinderkrebsinfo.de/g
poh_society/gpoh_who_w
e_are/index_eng.html  
Greece Hellenic society of Pediatric 
Haematology-Oncology 
www.eepao.gr/  
Hungary HPOG (Hungarian Paediatric 
Oncology Network) 
 
Israel ISPHO (Israel Society of Pediatric 
Hematology and Oncology)  
www.ispho.org.il/english/  
Italy AIEOP (Associazione Italiana 
Ematologia Oncologia Pediatrica)  
www.aieop.org  
Latvia Latvian Society of Paediatric 
Oncology 
www.ihot.lt/lt/bspoh  
Luxembourg (SIOPE 
institutional membership) 
Foundation Kriibskrank Kanner http://www.fondatioun.lu/  
The Netherlands SKION (Stichting Kinderoncologie 
Nederland) 
www.skion.nl  
Nordic countries 
(Denmark, Norway, 
Sweden, Iceland, Finland) 
+ Lithuania  
NOPHO (Nordic Society of 
Paediatric Haematology & 
Oncology) 
http://nopho.org/  
Poland Polish Society of Paediatric 
Oncology and Haematology 
 
Portugal SHOP (Sociedade de www.spp.pt 
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Hematologia e Oncologia 
Pediatrica) 
Romania Romanian Society of Paediatric 
Haematology-Oncology 
 
Serbia Serbian Society of Haematology 
and Oncology 
 
Slovak Republic Slovak Paediatric Association – 
Section of Paediatric Haemato-
Oncology 
 
Slovenia Slovenian Society of Paediatric 
Oncology 
 
Spain SEHOP (Sociedad Española de 
Hematología y Oncología 
Pediátricas) 
www.sehop.org  
Switzerland SPOG (Schweizerischen 
Pädiatrischen Onkologie Gruppe) 
www.spog.ch  
Turkey TPOG (Turkish Paediatric 
Oncology Group) 
www.tpog.org.tr  
United Kingdom & Ireland CCLG (Children’s Cancer and 
Leukaemia Group)  
www.cclg.org.uk  
 
